Short Interest in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Decreases By 52.1%

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 3,994 shares, a decline of 52.1% from the May 31st total of 8,343 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average trading volume of 48,201 shares, the days-to-cover ratio is presently 0.1 days.

Eloxx Pharmaceuticals Trading Down 12.6%

Eloxx Pharmaceuticals stock traded down $1.75 during trading hours on Wednesday, hitting $12.13. The company had a trading volume of 60,422 shares, compared to its average volume of 15,930. The business’s 50-day moving average is $18.49. The stock has a market capitalization of $8.37 million, a price-to-earnings ratio of -0.79 and a beta of -1,932.72. Eloxx Pharmaceuticals has a one year low of $11.74 and a one year high of $17.50.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.